PYXS - Pyxis Oncology, Inc. Stock Price, Fair Value and News

$1.62+0.08 (+5.19%)
Market Closed
Max Portfolio Pct.
Check
Valuation
Check

Stock Quality:

GPSDBMFI
Max Portfolio Pct.
Check
Valuation
Check
GPSDBMFI

PYXS Price Action

Last 7 days

-0.6%


Last 30 days

-0.6%


Last 90 days

-56.5%


Trailing 12 Months

-61.5%

PYXS Stock Price

PYXS RSI Chart

MayJunJulAugSepOctNovDec202501020304050607080

PYXS Valuation

Market Cap

91.6M

Price/Earnings (Trailing)

-1.6

Price/Sales (Trailing)

4.68

Price/Free Cashflow

-1.7

PYXS Price/Sales (Trailing)

202220232024202502004006008001K

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

PYXS Fundamentals

PYXS Revenue

Revenue (TTM)

19.6M

Rev. Growth (Yr)

8.14%

Rev. Growth (Qtr)

-100%

20222023202405M10M15M20M

PYXS Earnings

Earnings (TTM)

-57.4M

Earnings Growth (Yr)

8.01%

Earnings Growth (Qtr)

-22.55%

2021202220232024-120M-100M-80M-60M-40M-20M

PYXS Profitability

Return on Equity

-37.32%

Return on Assets

-29.37%

Free Cashflow Yield

-58.83%

PYXS Investor Care

Shares Dilution (1Y)

34.16%

Diluted EPS (TTM)

-1.03

Revenue Breakdown

As of: Sep 30, 2024
20222023202405M10M15M
Total
TotalValuePercent

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
2022AprJulOct2023AprJulOct2024AprJul02M4M6M8M10M12M14M16M18M20M22M
Net sales
YearQ1Q2Q3Q4
202421.1M19.4M19.6M0
20234.4M06.0M6.8M
20221.0M01.9M2.8M
2021000181.0K
Get all data in R, Python etc through our Historical Stock Data APIs
Pyxis Oncology, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody, which is in Phase 1 clinical trial for the treatment of solid tumors, including non-small cell lung cancer (NSCLC) without driver mutations/translocations, breast cancer, endometrial cancer, thyroid cancer, kidney cancer, cholangiocarcinoma, bladder cancer, colorectal cancer, and head and neck squamous cell carcinoma. The company's antibody drug conjugate product candidate is PYX-201, an investigational human immunoglobulin G1 isotype site-specifically conjugated, which is in Phase 1 clinical trial for solid tumors, including NSCLC, hormone receptor-positive breast cancer, ovarian cancer, thyroid cancer, pancreatic ductal adenocarcinoma, soft tissue sarcoma, hepatocellular carcinoma, and kidney cancer. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Pyxis Oncology, Inc. Frequently Asked Questions


What is the ticker symbol for Pyxis Oncology, Inc.? What does PYXS stand for in stocks?

PYXS is the stock ticker symbol of Pyxis Oncology, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Pyxis Oncology, Inc. (PYXS)?

As of Wed Jan 29 2025, market cap of Pyxis Oncology, Inc. is 91.58 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PYXS stock?

You can check PYXS's fair value in chart for subscribers.

Is Pyxis Oncology, Inc. a good stock to buy?

The fair value guage provides a quick view whether PYXS is over valued or under valued. Whether Pyxis Oncology, Inc. is cheap or expensive depends on the assumptions which impact Pyxis Oncology, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PYXS.

What is Pyxis Oncology, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Jan 29 2025, PYXS's PE ratio (Price to Earnings) is -1.6 and Price to Sales (PS) ratio is 4.68. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PYXS PE ratio will change depending on the future growth rate expectations of investors.